# US 2026/0205746 A1 · Pi3k-alpha inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0205746 A1
- Document ID: US20260205746A1
- Status: Published application
- Kind: A1
- Application number: 19/416,280
- Filed: 2025-12-11
- Published: 2026-07-16
- Earliest claimed: 2020-04-29
- Assignees: Relay Therapeutics, Inc.; D. E. Shaw Research, LLC
- Applicants: Relay Therapeutics, Inc.; D. E. Shaw Research, LLC
- Inventors: Alessandro BOEZIO; Lucian V. DIPIETRO; Hakan GUNAYDIN; Thomas H. MCLEAN; Levi Charles Thomas PIERCE; Fabrizio GIORDANETTO; Yakov PECHERSKY; Megan BERTRAND-LAPERLE; Alexandre LARIVEE; Kashif TANVEER; Michael Paul DENINNO; Tarek MOHAMED
- Web page: https://patentgrep.com/patent/US20260205746A1

## CPC

- H04R 25/554: {using a wireless connection, e.g. between microphone and amplifier or using Tcoils}
- A61B 5/0026: {characterised by the transmission medium}
- A61B 5/746: {Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms}
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/69: Boron compounds
- A61P 35/00: Antineoplastic agents
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 209/46: with an oxygen atom in position 1
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 217/24: Oxygen atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 239/82: with an aryl radical attached in position 4
- C07D 265/18: with hetero atoms directly attached in position 2
- C07D 275/06: with hetero atoms directly attached to the ring sulfur atom
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 493/04: Ortho-condensed systems
- C07D 493/08: Bridged systems
- C07D 495/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- H04R 2225/55: Communication between hearing aids and external devices via a network for data exchange
- H04R: LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; ELECTRIC HEARING AIDS; PUBLIC ADDRESS SYSTEMS (producing sounds with frequency not determined by supply frequency G10K)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3Kα enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Kα signaling with the compounds and compositions of the disclosure.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

A method of treating a cellular proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula I-1:
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, or a pharmaceutical composition thereof,
wherein:
E is —C(O)—;
is CH:
R1 is —L1—R1A;
L1 is a covalent bond;
R1A is phenyl, wherein the phenyl is substituted with r1 instances of R1c;
each Ric is independently (a), (b), (c), (d), or (e):
(a) D, halogen, CN, NO2, B(OR)2, C(O)R, C(O)NRR, C(O)NROR, C(O)OR, NRR, NRC(NR)NRR, NRC(O)R, NRC(O)NRR, NRC(O)OR, NRS(O)2R, NRS(O)2NRR, OR, OC(O)NRR, OC(O)R, P(O)RR, P(O)ROR, SR, SF5, S(O)R, S(O)NRR, S(O)(NR)R, S(O)2R, S(O)2F, or S(O)2NRR;
(b) a C1-6 aliphatic chain, wherein the C1-6 aliphatic chain is optionally substituted with one or more independently selected halogen substituents;
(c) a saturated or partially unsaturated, monocyclic 3- to 7-membered heterocyclyl, wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms or heteroatomic groups independently selected from the group consisting of N, NH, 0, and S, and further wherein the 3- to 7-membered heterocyclyl is optionally substituted with one or more independently selected halogen substituents;
(d) phenyl, wherein the phenyl is optionally substituted with one or more independently selected halogen substituents; or
(e) a monocyclic 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and further wherein the 5- or 6-membered heteroaryl is optionally substituted with one or more independently selected halogen substituents;
r1 is 0, 1, 2, 3, 4, or 5;
R2 is —L2—R2A;
L2 is —NHC(O)—;
R2A is a bicyclic 8- to 10-membered heteroaryl;
wherein the bicyclic 8- to 10-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and
wherein the bicyclic 8- to 10-membered heteroaryl is substituted with r2 instances of R2C;
each R2C is independently (a), (b), (c), (d), or (e):
(a) D, halogen, CN, NO2, B(OR)2, C(O)R, C(O)NRR, C(O)NROR, C(O)OR, NRR, NRC(NR)NRR, NRC(O)R, NRC(O)NRR, NRC(O)OR, NRS(O)2R, NRS(O)2NRR, OR, OC(O)NRR, OC(O)R, P(O)RR, P(O)ROR, SR, SF5, S(O)R, S(O)NRR, S(O)(NR)R, S(O)2R, S(O)2F, or S(O)2NRR;
(b) a C1-6 aliphatic chain, wherein the C1-6 aliphatic chain is optionally substituted with one or more independently selected halogen substituents;
(c) a saturated or partially unsaturated, monocyclic 3- to 7-membered heterocyclyl, wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms or heteroatomic groups independently selected from the group consisting of N, NH, O, and S, and further wherein the 3- to 7-membered heterocyclyl is optionally substituted with one or more independently selected halogen substituents;
(d) phenyl, wherein the phenyl is optionally substituted with one or more independently selected halogen substituents; or
(e) a monocyclic 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and further wherein the 5- or 6-membered heteroaryl is optionally substituted with one or more independently selected halogen substituents;
r2 is 0, 1, 2, 3, 4, or 5;
X is CH:
Y is CRY;
RY is —LY—RYA;
LY is a covalent bond;
RYA is a monocyclic 5- or 6-membered heteroaryl;
wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and
wherein the 5- or 6-membered heteroaryl is substituted with r6 instances of RYC;
each RYC is independently (a), (b), (c), (d), or (e):
(a) D, halogen, CN, NO2, B(OR)2, C(O)R, C(O)NRR, C(O)NROR, C(O)OR, NRR, NRC(NR)NRR, NRC(O)R, NRC(O)NRR, NRC(O)OR, NRS(O)2R, NRS(O)2NRR, OR, OC(O)NRR, OC(O)R, P(O)RR, P(O)ROR, SR, SF5, S(O)R, S(O)NRR, S(O)(NR)R, S(O)2R, S(O)2F, or S(O)2NRR;
(b) a C1-6 aliphatic chain, wherein the C1-6 aliphatic chain is optionally substituted with one or more independently selected halogen substituents;
(c) a saturated or partially unsaturated, monocyclic 3- to 7-membered heterocyclyl, wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms or heteroatomic groups independently selected from the group consisting of N, NH, O, and S, and further wherein the 3- to 7-membered heterocyclyl is optionally substituted with one or more independently selected halogen substituents;
(d) phenyl, wherein the phenyl is optionally substituted with one or more independently selected halogen substituents; or
(e) a monocyclic 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and further wherein the 5- or 6-membered heteroaryl is optionally substituted with one or more independently selected halogen substituents;
r6 is 0, 1, 2, 3, 4, or 5;
Z is N; and
each R is independently (a), (b), (c), (d), or (e):
(a) H;
(b) a C1-6 aliphatic chain, wherein the C1-6 aliphatic chain is optionally substituted with one or more independently selected halogen substituents;
(c) a saturated or partially unsaturated, monocyclic 3- to 7-membered heterocyclyl, wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms or heteroatomic groups independently selected from the group consisting of N, NH, O, and S, and further wherein the 3- to 7-membered heterocyclyl is optionally substituted with one or more independently selected halogen substituents;
(d) phenyl, wherein the phenyl is optionally substituted with one or more independently selected halogen substituents; or
(e) a monocyclic 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and further wherein the 5- or 6-membered heteroaryl is optionally substituted with one or more independently selected halogen substituents; or
any two R, taken together with the nitrogen atom to which they are attached, independently form a saturated or partially unsaturated 4- to 7-membered heterocyclyl or a 5- or 6-membered heteroaryl, wherein the 4- to 7-membered heterocyclyl or the 5- or 6-membered heteroaryl optionally contains 1, 2 or 3 additional heteroatoms or heteroatomic groups independently selected from the group consisting of N, NH, O, and S.

### Claim at position 3

38-42. (canceled)

### Claim 43 (depends on 37)

The method of claim 37, wherein the compound, or stereoisomer thereof, is of formula III or formula XXVIII:
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 44 (depends on 37)

The method of claim 37, wherein R1A is:

### Claim 45 (depends on 37)

The method of claim 37, wherein:
R1A is phenyl, wherein the phenyl is substituted with r1 instances of R1C;
each R1C is independently F, Cl, CH3, CHF2, and CF3; and
r1 is 1 or 2.

### Claim 46 (depends on 37)

The method of claim 37, wherein R1A is:

### Claim 47 (depends on 37)

The method of claim 37, wherein each Ric is independently halogen, CN, a C1-6 aliphatic chain, or an OC1-6 aliphatic chain, wherein each C1-6 aliphatic chain and OC1-6 aliphatic chain is optionally and independently substituted with one or more independently selected halogen substituents.

### Claim 48 (depends on 37)

The method of claim 37, wherein each Ric is independently halogen or a C1-6 aliphatic chain, wherein each C1-6 aliphatic chain is optionally and independently substituted with one or more independently selected halogen substituents.

### Claim 49 (depends on 37)

The method of claim 37, wherein R2A is:

### Claim 50 (depends on 37)

The method of claim 37, wherein R2 is:

### Claim 51 (depends on 37)

The method of claim 37, wherein each R2C is independently halogen, CN, a C1-6 aliphatic chain, or an OC1-6 aliphatic chain, wherein each C1-6 aliphatic chain and OC1-6 aliphatic chain is optionally and independently substituted with one or more independently selected halogen substituents.

### Claim 52 (depends on 37)

The method of claim 37, wherein each R2C is independently halogen, CN, a C1-3 aliphatic chain, OH, or an OC1-3 aliphatic chain, wherein each C1-3 aliphatic chain and OC1-3 aliphatic chain is optionally and independently substituted with one or more independently selected halogen substituents.

### Claim 53 (depends on 37)

The method of claim 37, wherein r2 is 0, 1, or 2.

### Claim 54 (depends on 37)

The method of claim 37, wherein RYA is a monocyclic 5- or 6-membered heteroaryl;
wherein the 5-membered heteroaryl contains 1 or 2 heteroatoms independently selected from the group consisting of N and O; or
wherein the 6-membered heteroaryl contains 1 or 2 N heteroatoms.

### Claim 55 (depends on 37)

The method of claim 37, wherein RYA is pyrazolyl or imidazolyl.

### Claim 56 (depends on 37)

The method of claim 37, wherein RYA is pyrazolyl.

### Claim 57 (depends on 37)

The method of claim 37, wherein each RYc is independently halogen, CN, a C1-3 aliphatic chain, OH, or an OC1-3 aliphatic chain, wherein each C1-3 aliphatic chain and OC1-3 aliphatic chain is optionally and independently substituted with one or more independently selected halogen substituents.

### Claim 58 (depends on 37)

The method of claim 37, wherein each RYc is independently halogen, a C1-3 aliphatic chain, or an OC1-3 aliphatic chain, wherein each C1-3 aliphatic chain is optionally and independently substituted with one, two, or three independently selected halogen substituents.

### Claim 59 (depends on 37)

The method of claim 37, wherein each RYc is independently F, Cl, CH3, CHF2, CF3, OCH3, or OCF3.

### Claim 60 (depends on 37)

The method of claim 37, wherein r6 is 0 or 1.

### Claim 61 (depends on 37)

The method of claim 37, wherein the cellular proliferative disease is cancer, wherein the cancer is selected from sarcoma; lung; bronchus; prostate; breast including sporadic breast cancers and sufferers of Cowden disease; pancreas; gastrointestinal; colon; rectum; carcinoma; colon carcinoma; adenoma; colorectal adenoma; thyroid; liver; intrahepatic bile duct; hepatocellular; adrenal gland; stomach; gastric; glioma; glioblastoma; endometrial; melanoma; kidney; renal pelvis; urinary bladder; uterine corpus; uterine cervix; vagina; ovary including clear cell ovarian cancer; multiple myeloma; esophagus; leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; carcinoma of the brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; villous colon adenoma; neoplasia; neoplasia of epithelial character; lymphoma; mammary carcinoma; basal cell carcinoma; squamous cell carcinoma; actinic keratosis; neck; head; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstrom macroglobulinemia.

### Claim 62 (depends on 37)

The method of claim 37, wherein the subject has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.
